RESUMEN
Developed as an insecticide synergist in the early 1940s, PBO increases the effectiveness of pyrethrins. Herein, the findings from a guideline developmental toxicity study in rat conducted in 1991 are reported. Timed-pregnant CD® (Sprague Dawley) rats were randomly assigned to a control and three treatment groups of 25 females each. A single daily dose of 200, 500 and 1000 mg/kg/day was administered orally (gavage) on days 6-15 of gestation. A vehicle group received deionized water. Cesarean sections were performed on all surviving females on gestation day 21 and fetuses were evaluated. All rats survived to GD 21 of gestation. Pregnancy rates in each group ranged from 88 % to 96 %. One dam in the 500 mg/kg/day dose had a single conceptus litter (one early resorption). Adverse clinical observations (urogenital wetness and staining) occurred in the 1000 mg/kg/day dose group. Maternal body weight decrease and food reductions occurred over the dosing period in the 500 and 1000 mg/kg/day groups. There were no treatment-related maternal necropsy findings. Terminal body weights and gravid uterine weights were comparable among the groups. Corrected body weight gain was decreased (>10 %) at 500 and 1000 mg/kg/day. Increased liver weights and relative liver weights were observed in the 1000 mg/kg/day dose group. There were no treatment-related effects on early resorptions, late resorptions, live fetuses per litter or sex ratio, or fetal weight per litter among the dose groups and no fetal malformations or variations attributed to PBO at any dose level.
Asunto(s)
Butóxido de Piperonilo , Reproducción , Animales , Peso Corporal , Femenino , Peso Fetal , Feto , Butóxido de Piperonilo/toxicidad , Embarazo , Ratas , Ratas Sprague-DawleyRESUMEN
Piperonyl butoxide (PBO) was developed in the 1940s. PBO increases the effectiveness of pyrethrins, thus it is called a synergist. Herein, the findings from a guideline developmental toxicity study in rabbits conducted in 1986 are reported. Inseminated New Zealand White rabbits were randomly assigned to a control and three treatment groups of 16 does each. Dose levels of 50, 100 and 200 mg/kg/day were selected based on a dosage-range study to avoid excessive maternal toxicity and administered orally (gavage) as a single daily dose on days 7-19 of gestation at a volume of 0.5 mL/kg. The control group received the vehicle only, Mazola® corn oil. Cesarean sections were performed on all surviving females on gestation day 29 and fetuses were evaluated. Survival for all study groups was 100%. Treatment-related maternotoxicity was manifested at the 100 and 200 mg/kg/day levels as decreased defecation and dose-related body weight losses during the treatment period (gestation days 7-13 and 7-19). The Cesarean section parameter values and fetal morphological observations of the treated groups did not differ significantly from the concurrent control group and were within the historical control range for this rabbit strain. No maternal or fetal adverse effects were seen at the 50 mg/kg/day dose level. Although maternal toxicity resulting from treatment was apparent at the 100 and 200 mg/kg/day dose levels, neither fetotoxicity nor teratogenicity were elicited in rabbits by piperonyl butoxide at dose levels as high as 200 mg/kg/day.
Asunto(s)
Butóxido de Piperonilo , Piretrinas , Animales , Cesárea , Femenino , Butóxido de Piperonilo/toxicidad , Embarazo , Conejos , ReproducciónRESUMEN
Piperonyl butoxide (PBO) an insecticide synergist was evaluated in a guideline multigenerational toxicity study in rats. F0 and F1 adult generations consisted of groups of 26 male and 26 female CD (Sprague Dawley) rats that were exposed to PBO in the diet at concentrations of 0, 300, 1000 or 5000 ppm for 85 (F0) or 83 (F1) days prior to cohabitation and throughout two mating periods (F1a, F2a and F1b, F2b). Exposure to test diets continued through the mating, gestation, and lactation periods for the females. F2 generation pups were euthanized following weaning. There were no effects on survival, clinical observations, gross or histological findings, fertility, pup viability, lactation indices or sex ratio in adults or pups in any generation. All effects of PBO occurred in the 5000-ppm exposure group. These effects included reduced body weight gains for F0 and F1 males and females during pre-cohabitation resulting in reduced body weights during both gestation periods. Food consumption of the F1b group males was slightly or significantly less than control values from week 3 onward. F1a generation pup weights were reduced on days 4, 7, 14 and 21 postpartum. Pup weights in the F1 and F2 generations were significantly reduced on days 14 and 21 postpartum when diets were being consumed by pups. The no-observable-adverse-effect level (NOAEL) for general toxicity was 1000 ppm based on reductions in body weights (parental and offspring) at 5000 ppm; and the NOAEL for reproductive toxicity was 5000 ppm with no direct effects on reproduction.
Asunto(s)
Insecticidas , Butóxido de Piperonilo , Animales , Peso Corporal , Dieta , Femenino , Masculino , Butóxido de Piperonilo/toxicidad , Ratas , Ratas Sprague-Dawley , ReproducciónRESUMEN
Sodium azide (NaN(3)) is being proposed for use as an active ingredient to control a broad spectrum of soil borne pathogens including insects, weeds, nematodes, fungi, and bacteria. The purpose of this study was to determine the maternal and developmental toxicity of NaN(3) in rats. Sperm-positive Sprague-Dawley rats were treated with NaN(3) via oral gavage once daily from Gestation Day (GD) 6 through 19 at respective dose levels of 0, 1, 5, and 17.5mg/kg/day. From GD 10-12, the high-dose was reduced to 10mg/kg/day due to maternal mortality. Cesarean section was performed on GD 20 and implantation and resorptions sites, live and dead fetuses were counted. Fetuses were weighed, sexed externally and processed for gross external, visceral and skeletal examinations. A high rate of maternal mortality; reduced gestation body weight, gestation body weight changes and food consumption; decreased corrected body weight and corrected weight gain were observed at 17.5/10mg/kg/day. Fetal weight was also reduced at 17.5/10mg/kg/day. There were no maternal deaths, clinical signs or body weight effects that were considered related to NaN(3) at 1 and 5mg/kg/day. No increase in the incidence of malformations and variations were observed at any of the doses evaluated. Based on the results of this study, the No Observed Adverse Effect Level (NOAEL) and the Lowest Observed Adverse Effect Level (LOAEL) for maternal and developmental toxicity of NaN(3) in rats were considered to be 5 and 17.5/10mg/kg/day, respectively.